| Trial | Treatments | Patients | Method |
|---|
| Nauck, 2007 | glipizide (n=-9) vs. sitagliptin (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: 52 weeks |
| Feinglos, 2005 | 2.5 mg glipizide GITS (n=61) vs. placebo (n=61) | type 2 diabetes inadequately controlled (A1c 7-8.5%) on metformin (> or =1000 mg/day for > or =3 months) | double-blind Sample size: 61/61 Primary endpoint: FU duration: 16 weeks |
| Rosenstock, 1993 | glipizide, 2.5 or 5 mg/day (n=139) vs. glyburide, 1.25 or 2.5 mg/day (n=0) | elderly patients with NIDDM that was controlled for at least 3 months with oral sulfonylurea therapy | open Parallel groups Sample size: 139/0 Primary endpoint: FU duration: 4 months |
| Birkeland, 1994 | glipizide (n=-9) vs. glyburide (n=-9) | NIDDM patients | Sample size: -9/-9 Primary endpoint: FU duration: |
| Birkeland, 1994 | glipizide (n=-9) vs. glyburide (n=-9) | NIDDM patients | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 15 months |
| Simonson, 1997 | once-daily doses of 5, 20, 40, or 60 mg glipizide GITS (n=-9) vs. placebo (n=-9) | NIDDM patients | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 4+8 weeks |
| Testa, 1998 | 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n=377) vs. placebo (n=192) | patients with type 2 diabetes mellitus | Parallel groups Sample size: 377/192 Primary endpoint: FU duration: 12 weeks |
| Goldstein | glipizide/metformin 5/500 mg tablets (n=-9) vs. metformin 500-mg (n=-9) glipizide 30-mg, metformin 500-mg, or glipizide/metformin 5/500 mg | patients with type 2 DM that is uncontrolled by at least half the maximum labeled daily dose of a sulfonylurea | open Cross over Sample size: -9/-9 Primary endpoint: FU duration: |
